Complete remission rates, survival, and relapse risk by cytogenetic abnormalities in Medical Research Council trial AML11
| Abnormality . | Total no. . | CR and reason for failure . | Relapse risk at 5 years, % (SE) . | Overall survival at 5 years, % (SE) . | ||
|---|---|---|---|---|---|---|
| CR rate, % . | Induction deaths, % . | Resistant disease, % . | ||||
| Overall | 1065 | 55 | 18 | 26 | 79 (1.8) | 13 (1.1) |
| Favorable | ||||||
| t(15;17) | 43 | 63 | 33 | 5 | 26 (9.1)3-153 | 38 (8.2)3-155 |
| t(8;21) | 23 | 87 | 03-155 | 13 | 84 (12.4) | 35 (9.9) |
| inv(16) | 12 | 75 | 17 | 8 | 89 (10.5) | 17 (10.8) |
| Intermediate | ||||||
| No abnormality | 507 | 63 | 20 | 17 | 78 (2.5) | 15 (1.7) |
| Sole +8 | 41 | 51 | 17 | 32 | 95 (4.9) | 5 (3.4) |
| 11q233-150 | 7 | 86 | 0 | 14 | 100 (0.0) | 0 (0.0) |
| Other intermediate3-151 | 221 | 54 | 16 | 303-153 | 84 (3.6) | 11 (2.2) |
| Adverse | ||||||
| Noncomplex adverse3-152 | 66 | 453-155 | 14 | 413-153 | 81 (8.1) | 7 (3.9) |
| Complex (with no favorable) | 145 | 263-153 | 19 | 563-153 | 91 (5.1)3-153 | 2 (1.2)3-153 |
| Abnormality . | Total no. . | CR and reason for failure . | Relapse risk at 5 years, % (SE) . | Overall survival at 5 years, % (SE) . | ||
|---|---|---|---|---|---|---|
| CR rate, % . | Induction deaths, % . | Resistant disease, % . | ||||
| Overall | 1065 | 55 | 18 | 26 | 79 (1.8) | 13 (1.1) |
| Favorable | ||||||
| t(15;17) | 43 | 63 | 33 | 5 | 26 (9.1)3-153 | 38 (8.2)3-155 |
| t(8;21) | 23 | 87 | 03-155 | 13 | 84 (12.4) | 35 (9.9) |
| inv(16) | 12 | 75 | 17 | 8 | 89 (10.5) | 17 (10.8) |
| Intermediate | ||||||
| No abnormality | 507 | 63 | 20 | 17 | 78 (2.5) | 15 (1.7) |
| Sole +8 | 41 | 51 | 17 | 32 | 95 (4.9) | 5 (3.4) |
| 11q233-150 | 7 | 86 | 0 | 14 | 100 (0.0) | 0 (0.0) |
| Other intermediate3-151 | 221 | 54 | 16 | 303-153 | 84 (3.6) | 11 (2.2) |
| Adverse | ||||||
| Noncomplex adverse3-152 | 66 | 453-155 | 14 | 413-153 | 81 (8.1) | 7 (3.9) |
| Complex (with no favorable) | 145 | 263-153 | 19 | 563-153 | 91 (5.1)3-153 | 2 (1.2)3-153 |
Percentages may not add to 100 because of rounding. Pvalues are for Fisher exact test (CR and reasons for failure) or log-rank test (relapse risk and overall survival) comparing each abnormality with normal karyotype (ie, no abnormality). MostP values remain at a similar level of significance when adjusted for age, type of leukemia (de novo or secondary), and WBC at presentation, except for the following: induction death: t(15;17) vs normal, P = .08 unadjusted, P = .007 adjusted; overall survival: t(15;17) vs normal, P = .005 unadjusted, P = .1 adjusted.
CR indicates complete remission.
Excludes patients with 11q23 in a favorable karyotype (n = 1) and in an adverse karyotype (n = 3).
Includes all patients not otherwise classified as favorable or adverse risk.
Includes patients with −7, del(5q), −5, and abnormal (3q) alone and in combination with up to 3 other cytogenetic abnormalities.
P < .001.
P < .01.